1 Subjects: “...Canada...”

2 Subjects: “...Canada...”

3 Subjects: “...Canada...”

4 Subjects: “...Canada...”

5 Subjects: “...Canada...”

6 Subjects: “...Canada...”

7 Subjects: “...Canada...”

8 Subjects: “...Canada...”

9 Subjects: “...Canada...”

10 Subjects: “...Canada...”

11 Subjects: “...Canada...”

12 “... to death. Recently the numbers of opioid-related deaths or hospitalizations have increased in Canada...”

13 “... birth or 1000 ml after a Cesarean section in Canada. In clinical practice, PPH should be considered when...”

14 “... birth or 1000 ml after a Cesarean section in Canada. In clinical practice, PPH should be considered when...”

15 “... to death. Recently the numbers of opioid-related deaths or hospitalizations have increased in Canada...”

16 “... to autoantibody production and abnormal B lymphocyte function. In Canada, the Common Drug Review (CDR) committee...”

17 “... similar to a type of THC (delta-9-THC). Nabilone is also approved in Canada. Dronabinol isindicated...”

18 “... similar to a type of THC (delta-9-THC). Nabilone is also approved in Canada. Dronabinol isindicated...”

19 “... to autoantibody production and abnormal B lymphocyte function. In Canada, the Common Drug Review (CDR) committee...”

20